Effect of frequent hemodialysis on residual kidney function

Kidney International

Volumn 83, Issue 5, 2013, Pages 949-958

  Daugirdas, John T ^a   Greene, Tom ^b   Rocco, Michael V ^c   Kaysen, George A ^d   Depner, Thomas A ^d   Levin, Nathan W ^e   Chertow, Glenn M ^f   Ornt, Daniel B ^g   Raimann, Jochen G ^e   Larive, Brett ^h   Kliger, Alan S ⁱ  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RENAL RESEARCH INSTITUTE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hemodialysis; hemodialysis adequacy; hemodialysis hazards; renal function decline

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; UREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MULTICENTER STUDY (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDUAL KIDNEY FUNCTION; URINE VOLUME;

EID: 84877018888     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.457     Document Type: Article

References (46)

1. Suri RS, Garg AX, Chertow GM et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int 2007; 71: 349-359.
2. Sergeyeva O, Gorodetskaya I, Ramos R et al. Challenges to enrollment and randomization of the frequent hemodialysis network (FHN) Daily Trial. J Nephrol 2012; 25: 302-309.
3. Rocco MV, Larive B, Eggers PW et al. Baseline characteristics of participants in the Frequent Hemodialysis Network (FHN) Daily and Nocturnal Trials. Am J Kidney Dis 2010; 57: 90-100.
4. Chertow GM, Levin NW, Beck GJ et al. In-center hemodialysis six times per week vs. three times per week. N Engl J Med 2010; 363: 2287-2300.
5. Rocco MV, Lockridge RS Jr, Beck GJ et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 2011; 80: 1080-1091.
6. Daugirdas JT, Chertow GM, Larive B et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 2012; 23: 727-738.
7. Chan CT, Greene T, Chertow GM et al. Determinants of left ventricular mass in patients on hemodialysis: Frequent Hemodialysis Network (FHN) Trials. Circ Cardiovasc Imaging 2012; 5: 251-261.
8. Hall YN, Larive B, Painter P et al. Effects of six vs. three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. Clin J Am Soc Nephrol 2012; 7: 782-794.
9. Kaysen GA, Greene T, Larive B et al. The effect of frequent hemodialysis on nutrition and body composition: frequent Hemodialysis Network Trial. Kidney Int 2012; 82: 90-99.
10. Vilar E, Farrington K. Emerging importance of residual renal function in end-stage renal failure. Semin Dial 2011; 24: 487-494.
11. USRDS. United States Renal Data System: 2011 Annual Data Report. 2011; http://www.usrds.org, Accessed: 09 Sep 2012.
12. Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053.
13. Lysaght MJ, Vonesh EF, Gotch F et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598-604.
14. Suzuki H, Kanno Y, Sugahara S et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056-1064.
15. Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564.
16. Rottembourg J, Issad B, Gallego JL et al. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1983; 19: 397-403.
17. Maiorca R, Cancarini G, Manili L et al. Comparative analysis after 6 years of results obtained with continuous ambulatory peritoneal dialysis and hemodialysis. Contrib Nephrol 1987; 55: 221-230.
18. Pierratos A, Ouwendyk M, Francoeur R et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9: 859-868.
19. Ting GO, Kjellstrand C, Freitas T et al. Long-term study of highcomorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003; 42: 1020-1035.
20. Maiorca R, Brunori G, Zubani R et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study. Nephrol Dial Transplant 1995; 10: 2295-2305.
21. Szeto CC, Wong TY, Leung CB et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000; 58: 400-407.
22. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162.
23. Shemin D, Bostom AG, Laliberty P et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 85-90.
24. Vilar E, Wellsted D, Chandna SM et al. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 2009; 24: 2502-2510.
25. van der Wal WM, Noordzij M, Dekker FW et al. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 2011; 26: 2978-2983.
26. Brener ZZ, Thijssen S, Kotanko P et al. The impact of residual renal function on hospitalization and mortality in incident hemodialysis patients. Blood Purif 2011; 31: 243-251.
27. Suda T, Hiroshige K, Ohta T et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 2000; 15: 396-401.
28. Wang AY, Sea MM, Ip R et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001; 12: 2450-2457.
29. Szeto CC, Lai KN, Wong TY et al. Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1999; 34: 1056-1064.
30. Penne EL, van der Weerd NC, Grooteman MP et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 2010; 6: 281-289.
31. Blumberg A, Burgi W. Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1987; 27: 245-249.
32. Fry AC, Singh DK, Chandna SM et al. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration. Blood Purif 2007; 25: 295-302.
33. Konings CJ, Kooman JP, Schonck M et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18: 797-803.
34. Wang AY, Wang M, Woo J et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639-647.
35. van Olden RW, Krediet RT, Struijk DG et al. Similarities in functional state of the kidney in patients treated with CAPD and hemodialysis. Adv Perit Dial 1996; 12: 97-100.
36. Davenport A, Sayed RH, Fan S. Is extracellular volume expansion of peritoneal dialysis patients associated with greater urine output? Blood Purif 2011; 32: 226-231.
37. Konings CJ, Kooman JP, Gladziwa U et al. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67: 1190-1191.
38. Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int 2012; 82: 147-157.
39. Diao Z, Zhang D, Dai W et al. Preservation of residual renal function with limited water removal in hemodialysis patients. Ren Fail 2011; 33: 875-877.
40. Uda S, Mizobuchi M, Akizawa T. Biocompatible characteristics of highperformance membranes. Contrib Nephrol 2011; 173: 23-29.
41. Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299.
42. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily vs. conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16: 2778-2788.
43. Greene T, Daugirdas JT, Depner TA et al. Solute clearances and fluid removal in the frequent hemodialysis network trials. Am J Kidney Dis 2009; 53: 835-844.
44. Kotler DP, Burastero S, Wang J et al. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr 1996; 64: 489S-497S.
45. Wang Z, St-Onge MP, Lecumberri B et al. Body cell mass: model development and validation at the cellular level of body composition. Am J Physiol Endocrinol Metab 2004; 286: E123-E128.
46. Benard A, Van Elteren P. A generalisation of the method of m rankings. Indag Math 1953; 15: 358-369.